Title : Treatment with PEG-IFN and ribavirin in patients with chronic hepatitis C, low grade of hepatic fibrosis, genotype 1 and 4 and favorable IFNL3 genotype: A pharmacogenetic prospective study.

Pub. Date : 2017 Jul

PMID : 28315743






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Considering a pharmacogenetic-guided approach, dual therapy with PEG-IFN and RBV can be considered a reliable option for patients ineligible for IFN-free treatments, who are motivated and well informed about all the aspects related to PEG-IFN administration. Ribavirin interferon alpha 1 Homo sapiens
2 Considering a pharmacogenetic-guided approach, dual therapy with PEG-IFN and RBV can be considered a reliable option for patients ineligible for IFN-free treatments, who are motivated and well informed about all the aspects related to PEG-IFN administration. Ribavirin interferon alpha 1 Homo sapiens